Doctors Note Logo

Published on: 10/1/2026

How long the hepatitis B vaccine lasts, and who needs a titer check

Hepatitis B vaccine protection is considered long lasting, likely for at least 30 years and possibly for life in healthy people who completed the full series, so routine boosters are not recommended for most adults. Titer testing (anti-HBs antibody levels) is advised for specific groups, including healthcare and public safety workers with blood exposure, infants born to HBsAg-positive mothers, people on dialysis, those who are immunocompromised, and sexual partners or household contacts of someone with chronic hepatitis B. Timing, the 10 mIU/mL threshold, and what to do about a non-response or waning antibodies all matter, and there are several important factors to consider, so see below to understand more before assuming you are protected or unprotected.

If you are unsure about your immunity, have had a possible exposure, or are noticing symptoms such as fatigue, nausea, dark urine, abdominal discomfort, or yellowing of the eyes or skin, getting clarity quickly can change what you do next. Take a free, instant, online symptom check to better understand what may be going on and which type of care or testing to pursue.

Last reviewed for medical accuracy: 10/01/2025

answer background

Explanation

How Long Does Hepatitis B Vaccine Last, and Who Needs a Titer Check?

Hepatitis B is a liver infection caused by the hepatitis B virus (HBV). Vaccination is the most effective way to prevent infection. Many people wonder: how long does hepatitis B vaccine last? Here’s what current research and expert guidelines tell us, plus who should check their antibody levels (titers).


Duration of Protection

  • Strong, lasting immunity
    After completing the standard 3-dose series, 90–95% of healthy adults develop protective antibody levels (anti-HBs ≥10 mIU/mL). Studies show:

    • At least 20–30 years of protection in healthy individuals.
    • Likely lifelong immunity for most people, even if antibody levels slowly decline.
    • No routine booster is needed for the general population.
  • Factors that may affect duration
    While most maintain immunity for decades, some groups may lose protection faster:

    • Adults over age 40.
    • Smokers.
    • Obesity.
    • Chronic health conditions (e.g., diabetes).

Who Needs a Titer Check?

A titer check measures anti-HBs levels to confirm protection. It’s not required for everyone—only certain groups at higher risk of exposure or with weakened immune systems.

1. Healthcare and Public-Safety Workers

  • People with regular contact with blood or bodily fluids:
    • Nurses, doctors, dentists.
    • Laboratory personnel.
    • Emergency responders, firefighters, police.

2. Dialysis Patients

  • Ongoing risk from frequent blood access.
  • Recommended to check anti-HBs annually or per dialysis unit protocol.

3. Immunocompromised Individuals

  • Those with HIV, cancer on chemotherapy, transplant recipients, or long-term steroids:
    • May fail to mount a full immune response.
    • Should have anti-HBs checked 1–2 months after vaccination and periodically thereafter.

4. Infants Born to HBsAg-Positive Mothers

  • Infants receive hepatitis B immune globulin (HBIG) plus vaccine at birth.
  • Titer check at 9–12 months to confirm protection.

5. Non-Responders

  • People whose anti-HBs levels remain <10 mIU/mL after the initial series.
  • Guidelines recommend:
    • A second 3-dose series.
    • Retest 1–2 months after the repeat series.
    • If still non-responsive, counsel about ongoing risk and consider specialist referral.

When and How to Check Titers

  1. Timing

    • First check: 1–2 months after completing the vaccine series.
    • Follow-up checks: per risk group (e.g., annually for dialysis patients).
  2. Blood test

    • Measures anti-HBs antibody concentration.
    • Protective level: ≥10 mIU/mL.
  3. Interpreting results

    • ≥10 mIU/mL: You’re protected—no booster needed (unless high-risk group protocol says otherwise).
    • <10 mIU/mL:
      • Revaccinate with a full series (or 2 additional doses in some guidelines).
      • Retest 1–2 months after revaccination.

Booster Doses: Not Usually Needed

Current U.S. and World Health Organization (WHO) guidelines agree:

  • Immunocompetent adults and children: No routine booster after a full series.
  • High-risk or immunocompromised: May need boosters or repeat vaccination based on titer results.
  • Occupational health programs: Often follow specific protocols for boosters in healthcare workers.

Special Considerations

  • Travelers to high-endemic areas (e.g., parts of Asia, Africa):
    If unvaccinated, start the series at least 1–2 months before travel.
  • Pregnancy:
    Hepatitis B vaccine is safe in pregnancy. If you’re at risk and not yet vaccinated, discuss vaccination with your provider.
  • Chronic diseases:
    Diabetes patients under age 60 may be offered vaccination per some state laws and employer policies.

Staying Informed and Managing Concerns

Understanding your level of protection can ease anxiety. If you have any signs of hepatitis (e.g., fatigue, jaundice, abdominal pain), don’t ignore them. You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to help assess your situation.

Always follow up with your healthcare provider for testing, vaccination, or any treatment.


Key Takeaways

  • For most healthy people, how long does hepatitis B vaccine last? At least 20–30 years, likely lifelong.
  • No routine boosters are needed for the general population.
  • Titer checks are advised for:
    • Healthcare and public-safety workers.
    • Dialysis patients.
    • Immunocompromised individuals.
    • Infants of infected mothers.
    • Non-responders to initial vaccine series.
  • If your anti-HBs level is <10 mIU/mL, you’ll need revaccination and retesting.

If you have questions about your hepatitis B immunity or any serious symptoms, speak to a doctor for personalized advice—especially if you develop signs of liver injury or feel unwell.

(References)

  • * Sasagawa N, Ozaki K, Matsuzaki S. Change in antibody titer 3 years after inoculation with recombinant hepatitis B vaccine. Tokai J Exp Clin Med. 1992 Dec;17(5-6):179-86. PMID: 1343425.

  • * Kaur H, Kumar R, Marshalla R. Seroconversion and seroprotection following hepatitis B vaccination. Indian J Gastroenterol. 1998 Jan;17(1):36. PMID: 9465521.

  • * Kaur H, Mani A. Seroprotection following Enivac-HB, a recombinant hepatitis B vaccine. Indian J Gastroenterol. 2000 Jan-Mar;19(1):41. PMID: 10659495.

  • * Duval B, Deceuninck G. Seroprotection rates after late doses of hepatitis B vaccine. Pediatrics. 2002 Feb;109(2):350-1. doi: 10.1542/peds.109.2.350. PMID: 11826227.

  • * Velu V, Nandakumar S, Shanmugam S, Thyagarajan SP. Persistence of anti-HBs titers after two different doses of Genevac B, a recombinant hepatitis B vaccine, in healthy adolescents. Indian J Gastroenterol. 2007 Jan-Feb;26(1):48. PMID: 17401247.

  • * Bloom A, Jackson K, Kiviat A, Zheng H, Sax P, Gandhi R. Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):110-3. doi: 10.1097/QAI.0b013e318183acc0. PMID: 19092450.

  • * Lee GH, Lim SG. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. Expert Rev Vaccines. 2021 May;20(5):487-495. doi: 10.1080/14760584.2021.1908133. Epub 2021 Apr 9. PMID: 33783302.

  • * Awad AM, Ntoso A, Connaire JJ, Hernandez GT, Dhillon K, Rich L, Henderson H, Lynn R, Hyer RN, Xie F, Erby K, Janssen RS, HBV-24 Study Group. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. Vaccine. 2021 Jun 8;39(25):3346-3352. doi: 10.1016/j.vaccine.2021.05.003. Epub 2021 May 14. PMID: 34001345.

  • * Diaz-Mitoma F, Popovic V, Spaans JN. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Vaccine. 2021 Jun 29;39(29):3892-3899. doi: 10.1016/j.vaccine.2021.05.067. Epub 2021 Jun 8. PMID: 34116873.

  • * Mo X, Men Z, Gao L, Gao Y, Yao T, Liu Y, Yuan Y, Xue T, Wang F, Wang S, Wang K, Liang X, Feng Y. Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China. Hum Vaccin Immunother. 2025 Dec;21(1):2447108. doi: 10.1080/21645515.2024.2447108. Epub 2025 Jan 17. PMID: 39819251; PMCID: PMC12934167.

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.